Medical Oncologist
Rituximab — understanding the numbers
Rituximab Success Rate: — What the Numbers Actually Mean
When you search for a rituximab success rate, you want to know whether this treatment will work for the person you love. That is a fair question. The honest answer is that the number depends heavily on which cancer rituximab is being used for — and that the figure your oncologist quotes is a median, not a ceiling.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- No single number exists — Rituximab is used in several B-cell cancers, and each has its own published response data with a different range.
- Median means the midpoint — Half of patients in a study did better than the median figure. It is not the best you can hope for.
- Your biology shapes the outcome — CD20 expression, cancer subtype, stage, and fitness all influence how rituximab performs for your specific case.
- Response is checked mid-treatment — Your team does not wait until the end to find out if rituximab is working — interim assessments happen along the way.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Rituximab outcomes vary widely by cancer type, stage, and individual biology. The figures your oncologist quotes are usually medians — the midpoint from a group of study patients, not a prediction about you. NCCN and ASCO guidance covers several cancers where rituximab is a standard treatment, each with its own published response data.
Why is there no single rituximab success rate?
Rituximab is not a treatment for one cancer. It is used in diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, mantle cell lymphoma, and several other B-cell conditions — each of which behaves very differently and responds differently.
Combining all of these into a single success rate would be like averaging the height of adults and children and calling it the height of a person. The number would not describe anyone accurately.
What matters is the response data for your specific diagnosis. Ask your oncologist which cancer type and subtype you have, and what the published evidence says for that particular group.
What does a median survival figure actually mean?
A median is the midpoint of a group. If a study reports a median overall survival, half of the patients in that study lived longer than that figure, and half did not reach it.
The median is not your ceiling. It is a statistical description of a studied group — a group that almost certainly had a different mix of ages, subtypes, and treatment contexts than yours.
You are not a median. You are one person, with one cancer, at one stage, with your own biology. The median tells your oncologist what a treatment is broadly capable of. It does not tell either of you what will happen to you specifically.
What factors affect how well rituximab works?
The cancer must express the CD20 protein on its surface for rituximab to bind to it. This is confirmed at diagnosis, and without CD20 expression, rituximab is not used.
Beyond CD20, the specific subtype and stage of your cancer, your age, your general fitness, and whether you have had prior treatment all influence the outcome your oncologist expects.
How your cancer responds after the first few cycles is itself useful information. Interim assessments tell your team whether the treatment is working and whether anything needs to change — they are not just a formality.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
How does your team check if rituximab is working?
Baseline imaging before treatment
A scan before the first cycle establishes the size and location of the cancer. Everything measured later is compared against this baseline.
Early treatment cycles
Rituximab is given as day care, typically alongside chemotherapy. Your team monitors for side effects and how you are tolerating the regimen.
Interim assessment
After a set number of cycles, a scan or blood tests check whether the cancer is responding. A clear response at this point is an encouraging signal and shapes what comes next.
Remaining cycles
If you are responding well, treatment continues on the agreed plan. If the response is poor, your oncologist will discuss whether the approach should change.
End-of-treatment scan
A full scan at the end of treatment establishes whether the response is partial or complete. The result determines the plan for what follows.
Follow-up monitoring
After treatment ends, regular check-ups and scans track how long remission lasts. Durable remission over time is one of the key outcomes your team watches for.
What should I ask my oncologist about my numbers?
- What is my exact cancer subtype, and how does it affect the way rituximab works?
- What response rate does the published evidence report for my subtype and stage?
- What does a partial response versus a complete response mean for my ongoing plan?
- When is the interim assessment, and what will it tell you about how I am responding?
- What is the plan if the interim scan does not show a clear response?
- How long do remissions typically last for my cancer type after this regimen?
What do families most want to know about rituximab and survival?
Is the median figure my loved one's personal prognosis?
No — and this distinction matters. A median survival figure comes from a study population that may have included patients at different stages, different ages, and different subtypes to your family member. It describes an average across that group, not a forecast for one individual. Your oncologist's assessment of prognosis takes your specific cancer, stage, and fitness into account. That conversation is far more relevant than any figure you find in a research paper or online.
Does rituximab work the second time if the cancer comes back?
Sometimes, and it depends largely on how long the remission lasted. A cancer that returns many months or years after rituximab-based treatment may still respond to a rituximab-containing regimen. One that returns quickly — or during treatment — is more likely to have developed resistance. Your oncologist will assess the pattern of relapse and may re-test the cancer before deciding whether rituximab should be part of the next line of treatment. We do not yet have a reliable way to predict in advance which situation a person will be in.
Why do the statistics I find online look different from what my doctor said?
Online statistics usually come from older published studies that may not reflect current drug combinations or supportive care. They often pool several cancer subtypes together, which can inflate or deflate the figure for your specific diagnosis. They do not know your age, fitness, stage, or your cancer's molecular behaviour. Your oncologist's figures are based on current evidence and your individual situation. Both can be accurate — they are answering different questions, and neither is misleading you.
What is the difference between overall survival and progression-free survival?
Overall survival measures how long patients lived from the start of treatment, regardless of what the cancer did in between. Progression-free survival measures how long patients lived without the cancer growing or returning. A treatment can improve progression-free survival without a study yet demonstrating an overall survival benefit — particularly when studies have not run long enough, or when later treatments helped patients who relapsed. Your oncologist will explain which measure is most relevant to the decision you are facing right now.
Should we get a second opinion on the prognosis?
A second opinion is a reasonable step when you are facing a major treatment decision, when the diagnosis is rare or uncertain, or when you want confidence that you are at a centre with experience in your specific cancer. It does not signal distrust, and most oncologists expect it — pathology and scans can be shared readily. What a second opinion cannot do is change the underlying biology of the cancer. But it can confirm the plan, identify something that was missed, or introduce an option that had not been discussed.
Explore 75 more Blood Cancer Targeted Medicines topics
Drug Deep Dive: Rituximab (MabThera)
- Diet and Nutrition While on Rituximab
- Drug, Food and Supplement Interactions With Rituximab
- Fertility, Pregnancy and Contraception on Rituximab
- Hepatitis B Reactivation and Rituximab: The Test You Must Not Skip
- How Does Rituximab Work? The Anti-CD20 Monoclonal Antibody Explained
- How Long Does Rituximab Take to Work?
- How Long Will You Stay on Rituximab?
- Low Antibodies and Repeated Infections After Rituximab
- MabThera vs Biosimilar Rituximab in India: Cost and Equivalence
- R-CHOP and Other Rituximab Combinations Explained
- Rituximab (MabThera, Ristova and biosimilars): The Complete Patient Guide
- Rituximab Infusion Day: Premedication, Duration and What to Expect
- Rituximab Infusion Reactions: Why the First Infusion Is Different
- Rituximab Maintenance: Two More Years of Infusions, and Why
- Rituximab Myths: Vaccines, Immunity and 'Permanent Damage'
- Rituximab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Rituximab Side Effects: The Complete List and Timeline
- Rituximab Success Rate and Survival: An Honest Look at the Numbers
- Rituximab in Elderly Patients and Those With Other Illnesses
- Tests and Monitoring While You Are on Rituximab
- When Rituximab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Rituximab? B-Cell Lymphoma and CLL
- Why the Same Drug Treats Arthritis and Lymphoma
- Will Insurance or a Government Scheme Pay for Rituximab?
- Work, Travel and Daily Life on Rituximab
Drug Deep Dive: Ibrutinib (Imbruvica)
- Diarrhoea, Joint Pain and Infection Risk on Ibrutinib
- Diet and Nutrition While on Ibrutinib
- Easy Bruising and Bleeding on Ibrutinib: What Is Normal and What Is Not
- Fertility, Pregnancy and Contraception on Ibrutinib
- How Does Ibrutinib Work? The BTK Inhibitor Explained
- How Long Does Ibrutinib Take to Work?
- How Long Will You Stay on Ibrutinib?
- Ibrutinib (Imbruvica, Ibrutix): The Complete Patient Guide
- Ibrutinib Interactions: Blood Thinners, Antifungals and Fish Oil
- Ibrutinib Myths: Lifelong Treatment, Bruising and 'It's Not Real Treatment'
- Ibrutinib Price in India: Brand, Generic and Monthly Cost
- Ibrutinib Side Effects: The Complete List and Timeline
- Ibrutinib Success Rate and Survival: An Honest Look at the Numbers
- Ibrutinib With Rituximab or Venetoclax: Continuous vs Fixed-Duration Therapy
- Ibrutinib in CLL, Mantle Cell Lymphoma and Waldenstrom's
- Ibrutinib in Elderly Patients and Those With Other Illnesses
- Ibrutinib vs Acalabrutinib vs Zanubrutinib: Comparing BTK Inhibitors
- Palpitations, Atrial Fibrillation and High Blood Pressure on Ibrutinib
- Surgery and Dental Procedures on Ibrutinib: The Bleeding Rule
- Taking Ibrutinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Ibrutinib
- When Ibrutinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Ibrutinib? CLL, Mantle Cell Lymphoma and Waldenstrom's Macroglobulinaemia
- Will Insurance or a Government Scheme Pay for Ibrutinib?
- Work, Travel and Daily Life on Ibrutinib
Drug Deep Dive: Imatinib (Gleevec)
- Adjuvant Imatinib After GIST Surgery: How Many Years?
- BCR-ABL PCR Monitoring: What 'Log Reduction' and 'MR4.5' Mean
- Can You Ever Stop Imatinib? Treatment-Free Remission Explained
- Diet and Nutrition While on Imatinib
- Fertility, Pregnancy and Contraception on Imatinib
- How Does Imatinib Work? The BCR-ABL and KIT Inhibitor Explained
- How Long Does Imatinib Take to Work?
- Imatinib (Gleevec, Veenat, Imatib): The Complete Patient Guide
- Imatinib Interactions: Paracetamol, Antacids and Herbal Medicines
- Imatinib Myths: Lifelong Dependence, Fertility and Generic Quality
- Imatinib Price in India: Brand, Generic and Monthly Cost
- Imatinib Side Effects: The Complete List and Timeline
- Imatinib Success Rate and Survival: An Honest Look at the Numbers
- Imatinib for GIST: How It Differs From CML Treatment
- Imatinib in Elderly Patients and Those With Other Illnesses
- Imatinib vs Nilotinib vs Dasatinib: Choosing a CML Drug
- Muscle Cramps and Bone Pain on Imatinib: What Actually Helps
- Nausea, Stomach Upset and Weight Gain on Imatinib
- Puffy Eyes and Swollen Legs on Imatinib: Managing Fluid Retention
- Taking Imatinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Imatinib
- When Imatinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Imatinib? Chronic Myeloid Leukaemia and GIST
- Will Insurance or a Government Scheme Pay for Imatinib?
- Work, Travel and Daily Life on Imatinib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
What is the success rate of rituximab for lymphoma?
There is no single figure that applies across all lymphomas. Rituximab is used in several subtypes — diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and others — and each has its own published response data. NCCN and ASCO guidance describes rituximab as a standard component of treatment for several of these, with meaningful improvements in outcomes compared to regimens without it. The number that matters is the one your oncologist can give you for your specific subtype and stage.
How do I know if rituximab is working?
Your team assesses how the cancer is responding through scans and, in some cancers, blood tests at planned points during treatment. For most lymphomas, an interim scan after a few cycles gives an early signal. At the end of treatment, a full scan establishes whether the response is partial or complete. If you are unsure when the next assessment is scheduled or what it will measure, ask your oncologist to walk you through the timeline.
Can rituximab lead to long-term remission?
In some subtypes, a proportion of patients achieve remissions that last many years. Whether that applies to your cancer type and stage depends on the specific diagnosis, and your oncologist can answer that directly from your pathology results. We do not use the word cure here, because it does not apply uniformly — but durable, long-term disease control is a realistic goal for some people receiving rituximab-based treatment.
What happens if rituximab does not work?
If your cancer does not respond to rituximab-based treatment, or if it returns after an initial response, there are further treatment options. These depend on the cancer type, how long remission lasted, your fitness, and what was used previously. Your oncologist will discuss the next line of treatment based on current NCCN and ESMO guidance. Being told a first regimen has not worked is frightening, but it is not the end of the treatment conversation.
Does rituximab work better for some people than others?
Yes. The CD20 protein must be present on the cancer cells for rituximab to bind — this is confirmed at diagnosis, and without it, rituximab is not used. Among those who are eligible, people with certain subtypes, earlier-stage disease, and fewer prior treatments generally do better. A good response at the interim assessment point is also associated with more durable outcomes. Your oncologist will interpret your specific results in that context rather than applying a general estimate.
Is rituximab available at CION?
Rituximab-based treatment is given as day care at CION centres, which means you do not need to stay overnight for each cycle. Response-assessment imaging such as PET-CT is coordinated with partner imaging centres. CION does not provide CAR-T or cell therapy; if your treatment plan involves those, you would be referred to a centre that offers them. Your oncologist will explain the full treatment schedule, including how many cycles are planned and when assessments fall.